Clinical Roundup: Gene-Edited Therapies for Beta...
Jul. 26, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
EdiGene
Main focus: Gene editing for the treatment of genetic diseases
Company stage: Clinical
Diseases: Beta-thalassemia, other undisclosed anaemias, lymphoma, solid tumours, neuromuscular diseases, Hurler syndrome
Genome editing technology: CRISPR-Cas9, LEAPER (RNA Editing)
Funding stage: Private
Location: Beijing, China
Website: https://www.edigene.com/
Pipeline: https://www.edigene.com/our_pipeline/
Partnerships: Arbor Biotechnologies, Neukio Biotherapeutics, Immunochina
EdiGene is a clinical-stage, gene-editing company, mainly focused on the development of novel therapies for haematopoietic diseases and cancer. The company holds licenses on proprietary CRISPR-Cas and RNA-editing platforms. The company's most advanced programme is ET-01 which has entered Phase I clinical development. This therapy is developed for the treatment of beta-thalassemia, and thus, is competing with similar programmes from CRISPR Therapeutics/Vertex Pharmaceuticals and Graphite Bio. The company is also developing next-generation CAR-T cell therapies, and these are still at pre-clinical stage.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Transfusion-Dependent Beta-Thalassemia, TDT, (NCT04390971)
Sponsors:
Institute of Hematology and Blood Diseases Hospital
Sponsors:
Institute of Hematology and Blood Diseases Hospital
IND Enabling
Phase I
Phase II
Phase III
